AI-powered workflow automation for pharma and biotech discovery research
Mithrl builds natural-language-driven automation for discovery data pipelines in pharma and biotech R&D. The stack centers on NVIDIA, AWS/Azure/GCP, and workflow engines (Nextflow, WDL, Snakemake) — a deliberate choice for reproducible, cloud-native bioinformatics at scale. Hiring is weighted toward engineering and data roles with senior-heavy seniority mix, while go-to-market infrastructure and private-cloud deployment automation dominate the project list, signaling a transition from research validation toward customer implementations.
Mithrl operates as an AI lab automation platform targeting pharma and biotech R&D teams. The core value prop is converting weeks-long manual discovery workflows into minutes-long natural-language-driven analyses, with full auditability and reproducibility. The company addresses a specific operational pain: scientists currently spend disproportionate time coding, troubleshooting, and rerunning analysis pipelines instead of designing experiments and testing hypotheses. Founded in 2023 and based in San Francisco with 11–50 employees, Mithrl is currently focused on scaling GTM infrastructure, hardening deployments into customer private-cloud environments, and integrating with existing bioinformatics ecosystems.
Mithrl uses NVIDIA, AWS, Azure, GCP for cloud infrastructure, plus Nextflow, WDL, and Snakemake for workflow orchestration. Core compute libraries include Python, R, Pandas, Polars, and PyArrow, with Kubernetes for containerization.
Current projects include building go-to-market infrastructure, automated curation and ingestion pipelines for biological data, private-cloud deployment automation, CI/CD improvements, and monitoring systems. Integration playbooks and validation testing for customer environments are also active priorities.
Other companies in the same industry, closest in size